Search Results 1571-1580 of 16615 for vitamin toxicity

  1. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies - Mayo Clinic

    - Active central nervous system tumors or metastases. - Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse ...

  2. Science Saturday - 2018 Archives - Mayo Clinic News Network

    Science Saturday: How bread yeast and book damage help clarify epigenetics featured image · Science Saturday: Research News Roundup — September 2018 featured ...

  3. Spastic colon: What does it mean? - Mayo Clinic

    IBS is a common digestive condition involving belly cramps and pain, bloating, constipation, and diarrhea. Medical professionals used the term "spastic colon" ...

  4. Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology - Mayo Clinic

    Current use of vitamin D analogs. · Fasting plasma glucose ≥ 126 mg/dL. · Renal failure (serum creatinine > 1.5mg/dl). · Chronic active liver disease (Bilirubin > ...

  5. Drugs and Supplements that Start with N - Mayo Clinic

    Natural Vitamin Blend E-400IU. Also known as. Vitamin e (oral route). Nature-Throid NT-1. Also known as. Thyroid (oral route). Nature-Throid NT-1/2. Also known ...

  6. Waldenstrom Macroglobulinemia Clinical Trials - Mayo Clinic Research

    The purpose of this study is to assess the safety and tolerability, identify dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD)/recommended ...

  7. ... POISONING AND TOXIC EFFECTS OF DRUGS WITH MCC,45411.13 MS918,POISONING AND TOXIC EFFECTS OF DRUGS WITHOUT MCC,18782.69 MS919,COMPLICATIONS OF TREATMENT WITH ...

  8. A Study of ONO-7475 in Patients With Acute Leukemias - Mayo Clinic

    Retinal disease (e.g., retinitis pigmentosa including Mertk mutations), retinal hemorrhage or any disorder which may inhibit follow up for retinal toxicity.

  9. Synergy with Grid Therapy and Immune Checkpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

    The primary objective of this study is to describe the safety and toxicity of grid + immunotherapy in stage IV NSCLC using CTCAE v5.0. Participation ...

  10. Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation - Mayo Clinic

    (Subjects with residual Grade 1 toxicity, for example Grade 1 peripheral neuropathy or residual alopecia, are allowed with approval of the Medical Monitor), ...